JUBLPHARMA - JUBILANT PHARMOVA LIMITED Share Price

Pharmaceuticals & Biotechnology

₹1120.40-6.00(-0.53%)

Market Closed as of Jun 17, 2025, 15:30 IST

What does JUBILANT PHARMOVA LIMITED do?

Pharmaceuticals•Healthcare•Small Cap

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. It serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.

Industry Group:Pharmaceuticals & Biotechnology

Employees:5,399

Website:www.jubilantpharmova.com

Valuation
Market Cap	17.43 kCr
Price/Earnings (Trailing)	25.67
Price/Sales (Trailing)	3.15
EV/EBITDA	13.97
Price/Free Cashflow	2.48 K
MarketCap/EBT	22.66

Fundamentals
Revenue (TTM)	5.53 kCr
Rev. Growth (Yr)	6.89%
Rev. Growth (Qtr)	3.21%
Earnings (TTM)	678.82 Cr
Earnings Growth (Yr)	51.66%
Earnings Growth (Qtr)	-1.76%

Profitability
Operating Margin	7.66%
EBT Margin	13.92%
Return on Equity	11.45%
Return on Assets	5.69%
Free Cashflow Yield	0.04%

Description	Share	Value
Radiopharma	45.7%	895.1 Cr
Contract Development and Manufacturing Organisation - Sterile Injectables	19.0%	372.3 Cr
Contract Research, Development and Manufacturing Organisation	17.5%	343.5 Cr
Allergy Immunotherapy	9.8%	191.9 Cr
Generics	8.0%	157.3 Cr
Total		2 kCr

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Shareholder Name	Holding %
SPB TRUSTEE COMPANY PVT LTD	20.52%
HSB TRUSTEE COMPANY PVT LTD	19%
EAST BRIDGE CAPITAL MASTER FUND I LTD	4.3%
GOVERNMENT PENSION FUND GLOBAL	3.47%
QUANT MUTUAL FUND - QUANT SMALL CAP FUND	1.85%
THELEME INDIA MASTER FUND LIMITED	1.46%
INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY MINISTRY OF CORPORATE AFFAIRS	1.25%
ABAKKUS EMERGING OPPORTUNITIES FUND-1	1.18%

Investor Care
Dividend Yield	1%
Dividend/Share (TTM)	10
Shares Dilution (1Y)	0.00%
Diluted EPS (TTM)	39.49

Financial Health
Current Ratio	1.8
Debt/Equity	0.48
Debt/Cashflow	0.03

Cash Flow for JUBILANT PHARMOVA

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Finance costs	61.1%	30	19	31
Change in inventories	622.6%	63	9.58	0
Depreciation	11.9%	48	43	6.25
Unrealised forex losses/gains	135.7%	1.2	0.44	0.01
Dividend income	-66.7%	33	97	97
Adjustments for interest income	-6.4%	0.5	0.53	0.86
Share-based payments	2433.3%	1.7	0.97	0.5
Net Cashflows from Operations	414.4%	154	-47.67	13
Income taxes paid (refund)	-31.2%	12	17	19
Other inflows (outflows) of cash	-	1	0	0
Net Cashflows From Operating Activities	314.8%	143	-65.12	-6.47
Cashflows used in obtaining control of subsidiaries	-112.9%	0	8.75	0
Proceeds from sales of PPE	-1150%	0	0.92	0.04
Purchase of property, plant and equipment	13.6%	68	60	1.95
Proceeds from sales of investment property	-	0.9	0	0
Cash receipts from repayment of advances and loans made to other parties	-5.3%	0	0.05	0
Dividends received	-66.7%	33	97	97
Interest received	-66.7%	0.3	0.58	0.87
Other inflows (outflows) of cash	1.8%	-0.1	-0.12	0
Net Cashflows From Investing Activities	-237.7%	-40.3	31	96
Proceeds from borrowings	-22%	100	128	6
Repayments of borrowings	-	34	0	0
Payments of lease liabilities	45.8%	9.4	6.76	2.93
Dividends paid	0%	80	80	80
Interest paid	70.6%	30	18	30
Other inflows (outflows) of cash	-	-25	0	0
Net Cashflows from Financing Activities	-458.2%	-77.8	23	-107.37
Net change in cash and cash eq.	291.4%	25	-11.54	-17.82

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Finance costs	-86.1%	27	188	145
Change in inventories	112.3%	9.08	-64.68	-95.65
Depreciation	-93.3%	38	554	382
Unrealised forex losses/gains	86.5%	0.14	-5.35	40
Adjustments for interest income	-81.8%	2.61	9.83	2.45
Share-based payments	-105.7%	0.85	3.65	1.12
Net Cashflows from Operations	-86.5%	118	865	1,032
Income taxes paid (refund)	-90.1%	21	204	194
Net Cashflows From Operating Activities	-85.5%	97	661	838
Cash receipts from share of profits of partnership firm or association of persons or LLP	-112.8%	0	8.82	0
Proceeds from sales of PPE	-100.2%	0.97	19	3.52
Purchase of property, plant and equipment	-89.1%	90	814	600
Proceeds from sales of investment property	-	0	0	44
Purchase of investment property	-	0	0	2.32
Proceeds from government grants	-90.9%	23	244	0
Interest received	-82.5%	2.57	9.98	4.02
Other inflows (outflows) of cash	245.6%	2.66	-0.14	170
Net Cashflows From Investing Activities	88.7%	-60.79	-544.41	-380.37
Proceeds from borrowings	-99.6%	12	3,005	247
Repayments of borrowings	-99.5%	14	2,773	5
Payments of lease liabilities	-92.6%	6.12	70	60
Dividends paid	-91.2%	7.98	80	80
Interest paid	-90.1%	24	234	135
Other inflows (outflows) of cash	24.7%	-2.74	-3.97	0
Net Cashflows from Financing Activities	71.9%	-43.25	-156.69	-32.6
Effect of exchange rate on cash eq.	-99.8%	1.16	71	57
Net change in cash and cash eq.	-123.3%	-5.75	30	482

Balance Sheet for JUBILANT PHARMOVA

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	-45.7%	20	36	11	11	111	23
Loans, current	11.1%	0.2	0.1	0.1	0.02	0.27	0
Total current financial assets	-37.2%	151	240	226	213	326	48
Inventories	1.6%	255	251	276	314	310	0
Total current assets	-16.7%	451	541	565	579	678	48
Property, plant and equipment	-0.2%	522	523	493	491	489	100
Capital work-in-progress	-30.6%	26	37	59	47	35	0.06
Goodwill	0%	137	137	137	137	137	0
Non-current investments	0%	1,657	1,657	1,657	1,657	1,654	1,646
Loans, non-current	0%	0.2	0.2	0.3	0.3	0.41	0.06
Total non-current financial assets	0.1%	1,669	1,668	1,668	1,666	1,664	1,652
Total non-current assets	-0.4%	2,441	2,451	2,449	2,430	2,440	1,782
Total assets	-3.3%	2,892	2,992	3,014	3,008	3,117	1,829
Borrowings, non-current	-0.8%	244	246	250	174	174	499
Total non-current financial liabilities	8.1%	267	247	282	209	213	505
Provisions, non-current	0%	27	27	24	23	23	5.16
Total non-current liabilities	-2.3%	295	302	306	233	236	510
Borrowings, current	-18.9%	78	96	123	128	59	2.17
Total current financial liabilities	-11.7%	249	282	327	330	388	26
Provisions, current	-1.7%	6.8	6.9	10	11	11	7.9
Current tax liabilities	0%	0.2	0.2	0.2	0.16	3.92	0.11
Total current liabilities	-5.4%	298	315	368	361	434	38
Total liabilities	-3.9%	593	617	674	594	671	548
Equity share capital	0%	16	16	16	16	16	16
Total equity	-3.2%	2,299	2,374	2,340	2,415	2,447	1,282
Total equity and liabilities	-3.3%	2,892	2,992	3,014	3,008	3,117	1,829

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	1032.6%	1,077	96	974	1,014	846	984
Loans, current	121.7%	1.2	0.08	1	1.14	1.48	1.4
Total current financial assets	887.7%	2,085	212	2,002	2,106	1,919	2,001
Inventories	807%	1,162	129	1,328	1,381	1,410	1,255
Current tax assets	5273.1%	37	1.67	24	12	0.36	0.18
Total current assets	867.1%	3,502	363	3,606	3,762	3,620	3,509
Property, plant and equipment	889.3%	2,128	216	2,250	2,298	2,240	2,201
Capital work-in-progress	1396.8%	1,857	125	1,095	773	487	292
Investment property	-	0	0	0	-	215	195
Goodwill	911.8%	2,480	246	2,452	2,429	2,393	2,243
Non-current investments	1252.5%	34	3.44	33	33	46	43
Loans, non-current	27.8%	0.3	0.03	0.4	0.43	0.59	0.55
Total non-current financial assets	1136%	56	5.45	54	52	65	62
Total non-current assets	999.5%	8,423	767	7,793	7,394	7,084	6,482
Total assets	933.2%	11,924	1,155	11,400	11,157	10,705	9,991
Borrowings, non-current	704.1%	2,542	317	3,170	3,110	2,996	2,464
Total non-current financial liabilities	753.7%	2,878	338	3,392	3,325	3,220	2,677
Provisions, non-current	1022.2%	102	10	93	92	102	96
Total non-current liabilities	857.4%	4,051	424	4,208	3,992	3,743	3,083
Borrowings, current	1075%	283	25	250	300	223	463
Total current financial liabilities	957.8%	1,704	162	1,589	1,510	1,198	1,318
Provisions, current	1034.8%	65	6.64	73	78	97	87
Current tax liabilities	148.1%	7.7	3.7	11	62	43	35
Total current liabilities	935.1%	1,947	189	1,790	1,772	1,491	1,592
Total liabilities	879.7%	5,997	613	5,998	5,765	5,234	4,674
Equity share capital	2486.2%	16	1.58	16	16	16	16
Non controlling interest	-536%	-13.5	-1.28	-8.7	-7.49	-4.21	-2.16
Total equity	995.4%	5,927	542	5,401	5,392	5,471	5,316
Total equity and liabilities	933.2%	11,924	1,155	11,400	11,157	10,705	9,991

Income Statement for JUBILANT PHARMOVA

Standalone figures (in Rs. Crores) / View Consolidated Data

QuarterlyAnnual

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	18.2%	196	166	167	206	175	186
Other Income	-60.5%	18	44	20	50	19	18
Total Income	1.9%	214	210	186	256	194	205
Cost of Materials	24.6%	77	62	66	74	69	95
Purchases of stock-in-trade	-	0	0	0	-1.5	3.9	1.5
Employee Expense	2%	52	51	49	46	50	46
Finance costs	-5.9%	7.4	7.8	7.6	8.1	8.3	7.1
Depreciation and Amortization	0%	13	13	13	13	12	12
Other expenses	-8.2%	57	62	56	55	54	53
Total Expenses	6.8%	206	193	186	214	196	204
Profit Before exceptional items and Tax	-51.9%	8.7	17	0	42	-2.3	0.2
Exceptional items before tax	-	0	0	-11.2	0	0	0
Total profit before tax	-51.9%	8.7	17	-11.2	42	-2.3	0.2
Current tax	23.3%	6.3	5.3	0	6.8	-0.4	0
Deferred tax	-1850%	-2.9	0.8	-1	2.2	0.5	0.6
Total tax	-52.9%	3.4	6.1	-1	9	0.1	0.6
Total profit (loss) for period	-52.2%	5.3	10	-10.2	32	-2.4	-0.4
Other comp. income net of taxes	0%	-0.2	-0.2	-0.2	0.1	-0.2	-0.2
Total Comprehensive Income	-54.4%	5.1	10	-10.4	33	-2.6	-0.6
Earnings Per Share, Basic	-97.1%	0.33	0.66	-0.64	2.05	-0.15	-0.03
Earnings Per Share, Diluted	-97.1%	0.33	0.66	-0.64	2.05	-0.15	-0.03

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020	Mar-2019
Revenue From Operations	-3.1%	785	810	88	2,710	3,140	3,439
Other Income	-25.5%	103	138	126	48	173	78
Total Income	-6.3%	888	948	214	2,757	3,313	3,517
Cost of Materials	-21.8%	310	396	0	1,329	1,683	1,875
Purchases of stock-in-trade	-60.7%	6.5	15	0	66	109	131
Employee Expense	13.9%	190	167	49	221	265	266
Finance costs	61.1%	30	19	31	102	136	129
Depreciation and Amortization	11.9%	48	43	6.25	100	107	86
Other expenses	-0.9%	223	225	45	611	820	799
Total Expenses	-2.6%	846	869	131	2,484	3,013	3,333
Profit Before exceptional items and Tax	-47.4%	42	79	82	273	301	183
Exceptional items before tax	-	0	0	0	0	-1.7	0
Total profit before tax	-47.4%	42	79	82	273	299	183
Current tax	-55.4%	6.8	14	14	45	26	31
Deferred tax	-84.7%	3.3	16	-9.91	13	-48.43	4.72
Total tax	-67.9%	10	29	3.75	59	-22.3	36
Total profit (loss) for period	-36.7%	32	50	78	214	321	148
Other comp. income net of taxes	-568.7%	-0.5	1.32	0.02	-1.75	-1.88	-0.57
Total Comprehensive Income	-40%	31	51	79	213	319	147
Earnings Per Share, Basic	-53.5%	1.99	3.13	4.93	13.47	20.16	9.27
Earnings Per Share, Diluted	-53.5%	1.99	3.13	4.93	13.47	20.16	9.27
Debt equity ratio	-	-	-	-	0	-	071
Debt service coverage ratio	-	-	-	-	0	-	0.0309
Interest service coverage ratio	-	-	-	-	0	-	0.0309

Consolidated figures (in Rs. Crores) / View Standalone Data

QuarterlyAnnual

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	4%	1,822	1,752	1,732	176	1,677	1,680
Other Income	-61%	9.2	22	14	1.44	36	9.9
Total Income	3.2%	1,831	1,774	1,746	177	1,713	1,690
Cost of Materials	-0.4%	467	469	465	50	432	464
Purchases of stock-in-trade	17.6%	81	69	62	5.39	72	58
Employee Expense	-0.7%	560	564	553	56	582	532
Finance costs	-8.3%	56	61	71	7.3	71	66
Depreciation and Amortization	0%	91	91	91	10	95	97
Other expenses	16.3%	400	344	366	40	342	349
Total Expenses	4.1%	1,681	1,615	1,642	166	1,625	1,601
Profit Before exceptional items and Tax	-5.7%	150	159	104	11	88	89
Exceptional items before tax	-30.9%	-18.9	-14.2	396	-16.89	0	0
Total profit before tax	-9.1%	131	144	500	-5.71	88	89
Current tax	-20.5%	32	40	26	11	45	35
Deferred tax	-488.9%	-2.5	1.9	-8.2	-10	-10.5	0.8
Total tax	-29.3%	30	42	18	0.81	35	36
Total profit (loss) for period	-1%	101	102	482	-6.18	66	62
Other comp. income net of taxes	117.2%	64	30	-3.9	-0.66	17	34
Total Comprehensive Income	24.4%	164	132	478	-6.84	83	96
Earnings Per Share, Basic	-1.8%	6.37	6.47	30.44	-3.69	4.22	3.94
Earnings Per Share, Diluted	-1.8%	6.36	6.46	30.35	-3.68	4.2	3.94

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020	Mar-2019
Revenue From Operations	-89.3%	670	6,282	6,059	6,099	9,154	9,111
Other Income	-84.1%	6.87	38	82	18	47	36
Total Income	-89.3%	677	6,320	6,141	6,116	9,202	9,147
Cost of Materials	-89.1%	182	1,666	1,349	1,349	3,119	3,283
Purchases of stock-in-trade	-90.8%	24	252	202	168	277	241
Employee Expense	-89.8%	222	2,166	2,043	1,923	2,128	1,926
Finance costs	-86.1%	27	188	145	184	287	220
Depreciation and Amortization	-93.3%	38	554	382	349	462	371
Other expenses	-90.1%	145	1,462	1,442	1,243	1,939	1,924
Total Expenses	-89.7%	646	6,248	5,501	5,235	7,957	7,963
Profit Before exceptional items and Tax	-56.3%	32	72	640	881	1,245	1,184
Exceptional items before tax	69.1%	-16.89	-56.82	0	-21.23	-34.64	-280.23
Total profit before tax	-6.7%	15	16	640	860	1,211	904
Current tax	-89.4%	20	181	173	270	323	282
Deferred tax	87.2%	-10.48	-88.42	45	27	-10.53	45
Total tax	-90.5%	9.78	93	217	297	312	327
Total profit (loss) for period	109.5%	7.27	-64.88	413	836	898	577
Other comp. income net of taxes	-98%	5.44	220	244	174	33	-13.78
Total Comprehensive Income	-92.3%	13	156	657	1,010	931	563
Earnings Per Share, Basic	180.1%	4.87	-3.83	26	52.48	56.39	36.86
Earnings Per Share, Diluted	179.9%	4.86	-3.83	26	52.48	56.39	36.86
Debt equity ratio	-	-	-	-	0	-	073
Debt service coverage ratio	-	-	-	-	0	-	0.0807
Interest service coverage ratio	-	-	-	-	0	-	0.0807

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical IndustriesPharmaceuticals	4.05 LCr	53.56 kCr	-4.71%	+9.04%	35.31	7.56	+10.28%	+28.38%
DIVISLAB	Divi's LabPharmaceuticals	1.77 LCr	9.42 kCr	+4.12%	+42.48%	85.63	18.78	+20.50%	+49.46%
CIPLA	CiplaPharmaceuticals	1.22 LCr	27.8 kCr	+0.14%	+2.61%	24.38	4.37	+7.01%	+33.22%
DRREDDY	Dr. Reddy's LabPharmaceuticals	1.14 LCr	32.07 kCr	+7.17%	+8.38%	20.87	3.55	+14.31%	+4.21%
AUROPHARMA	Aurobindo PharmaPharmaceuticals	64.49 kCr	31.57 kCr	-7.57%	-11.81%	18.49	2.04	+10.80%	+26.04%

JUBLPHARMA - JUBILANT PHARMOVA LIMITED Share Price

What does JUBILANT PHARMOVA LIMITED do?

Valuation

Fundamentals

Profitability

Revenue Breakdown

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

Investor Care

Financial Health

Cash Flow for JUBILANT PHARMOVA

Balance Sheet for JUBILANT PHARMOVA

Income Statement for JUBILANT PHARMOVA

Is JUBILANT PHARMOVA Better than it's peers?